Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
Complete Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-CoV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS
Trial Phase:
Investigator: Jim Boonyaratanakornkit
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants. The secondary objectives of the study are: •To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population •To characterize concentrations of casirivimab and imdevimab in serum over time •To assess the immunogenicity of casirivimab and imdevimab
Keywords:
- COVID-19
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
Jim Boonyaratanakornkit
RG1121987
NCT05074433
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-CoV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS
COVID-19